Clinical Trial

Study of SLN12140 in Healthy Adult Participants

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated April 25, 2025 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
A randomized, double-blind, placebo-controlled phase I clinical study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of SLN12140 in healthy participants with single subcutaneous/intravenous dose escalation and multiple subcutaneous administrations
Trial Details
NCT Number NCT06945445
Lead Sponsor Linno Pharmaceuticals, Inc.
Conditions Healthy Volunteer
Enrollment 56 participants
Start Date 2025-04
Primary Completion 2026-05 (estimated)
Study Completion 2026-06 (estimated)
Updated on ClinicalTrials.gov 2025-04-25